Collectively, these findings demonstrate that IFITM3 overexpression triggered a potent antitumor immune response and sensitized SCLC tumors to PD-1 blockade, highlighting its potential as a therapeutic target for immunotherapy. Here, IFITM3 is linked to small cell lung carcinoma.